Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Pfizer, Inc. (NYSE: PFE).

Full DD Report for PFE

You must become a subscriber to view this report.


Recent News from (NYSE: PFE)

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
SEATTLE , Dec. 17, 2018 /PRNewswire/ -- Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE:PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.  The ...
Source: PR Newswire
Date: December, 17 2018 08:00
Dividend Increases: December 10-14, 2018
Monitoring dividend increases for stocks on my watch is one way to identify candidates for further analysis. Companies that regularly increase their dividends show confidence in future earnings growth potential. The CCC List provides a good starting point, but I limit the number of stock...
Source: SeekingAlpha
Date: December, 17 2018 03:54
Time To Connect The Dots (Stocks To Watch Podcast)
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look ...
Source: SeekingAlpha
Date: December, 16 2018 08:04
Stocks To Watch: Time To Connect The Dots
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There are two monster meetings on the agenda next week that could shake things up f...
Source: SeekingAlpha
Date: December, 15 2018 09:12
Pfizer Declares First-Quarter 2019 Dividend
Board of Directors approves increase in quarterly cash dividend to $0.36 per share and authorizes new $10 billion share repurchase program The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company’s common stock, payable March 1...
Source: Business Wire
Date: December, 14 2018 12:10
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV(TM) (bevacizumab)
ZIRABEV ™ (bevacizumab) , a potential biosimilar to Avastin ®* (bevacizumab), is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018 Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Pro...
Source: Business Wire
Date: December, 14 2018 10:29
Today's Research Reports on Trending Tickers: Pfizer and Merck & Co.
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial Average gained 0.29 percent to close at 24,597.38, while the S&P 500 Index fell 0.02 ...
Source: ACCESSWIRE IA
Date: December, 14 2018 08:05
Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 ye...
Source: Business Wire
Date: December, 14 2018 08:00
Senate Dems introduce bill to block "excessive" increases in drug prices
Four democratic senators, Richard Blumenthal (D-CT), Kamala Harris (D-CA), Amy Klobuchar (D-MN) and Jeff Merkley (D-OR), have introduced a bill aimed at blocking drug price hikes. Specifically, it will allow the Department of Health and Human Services to prohibit price increases that it co...
Source: SeekingAlpha
Date: December, 13 2018 14:24
Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial
As the previous article provided a broad overview of Affimed and the opportunity for investors , this follow-up will concentrate almost exclusively on takeaways from the AFM13-focused R&D Day. Extreme market weakness on the R&D day overshadowed a positive event for Affimed ( AFMD ) ...
Source: SeekingAlpha
Date: December, 12 2018 10:29

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1743.5043.1143.9742.9836,319,393
2018-12-1444.0843.8044.1243.42531,333,031
2018-12-1344.4644.5744.9044.2122,404,113
2018-12-1244.3544.1644.84544.1519,147,119
2018-12-1144.0844.0144.5143.5722,680,157

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-17235,135860,30227.3317Cover
2018-12-14293,147654,43144.7942Short
2018-12-13220,698463,24547.6417Short
2018-12-1284,551336,14825.1529Cover
2018-12-11208,092575,18036.1786Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PFE.


About Pfizer, Inc. (NYSE: PFE)

Logo for Pfizer, Inc. (NYSE: PFE)

Not available

 

Contact Information

 

 

Current Management

  • William C. Steere Jr. / CEO

Current Share Structure

  • Market Cap: $208,712,694,993 - 05/25/2018
  • Issue and Outstanding: 5,849,571,048 - 05/07/2018

 


Recent Filings from (NYSE: PFE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: September, 06 2018
Free Writing Prospectus
Filing Type: FWPFiling Source: edgar
Filing Date: September, 05 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: September, 04 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: August, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 31 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 28 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 28 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 28 2018

 

 


Daily Technical Chart for (NYSE: PFE)

Daily Technical Chart for (NYSE: PFE)


Stay tuned for daily updates and more on (NYSE: PFE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: PFE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PFE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PFE and does not buy, sell, or trade any shares of PFE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/